-
InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
PharmaSources
May 21, 2024
The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.
-
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
PharmaSources
May 16, 2024
InnoCare announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
-
Decentralising research: Virtual clinical trials
Suzanne Elvidge
May 14, 2024
Clinical trials are vital as the basis of developing safe and effective drugs, but they can be slow and expensive.
-
Clinical Research Organization's (CROs) using Artificial Intelligence (AI) tools in restructuring the clinical trials
Shruti Talashi
April 11, 2024
Healthcare is embracing AI for better diagnosis, drug development, and patient care.
-
Osteolabs to Present New Clinical Data from Over 2.400 OsteoTest Routine Samples at the WCO-IOF-ESCEO Congress
Biotech Newswire
April 10, 2024
New data fully supporting potential for OsteoTest to qualify as new universal diagnostic method for early osteoporosis risk assessment and therapeutic control.
-
University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study
Biotech Newswire
April 07, 2024
Touchlight announced an agreement with University of Liverpool for the use of dbDNA in the development of a fully-personalised therapeuticneoantigen DNA vaccine for patients with non-small cell lung cancer.
-
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
PharmaSources
April 01, 2024
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination with other antitumor agents.
-
Why Diverse Representation in Clinical Research Matters
Suzanne Elvidge
March 19, 2024
Randomised controlled trials (RCTs), where study participants are randomly allocated to an experimental group or a control group, became the ‘gold standard’ of clinical research in the mid-20th century.
-
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China
Chunhua Lu
March 13, 2024
BTK inhibitor orelabrutinib as first-line therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China.
-
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
PharmaSources
January 24, 2024
Jan. 24, 2024 - InnoCare Pharma announced today that the first pediatric patient has been dosed in clinical trial with its second.